BUZZ-Immunic rises after board hire of MS drug veteran

Reuters03-31
BUZZ-Immunic rises after board hire of MS drug veteran

** Shares of biotech firm Immunic IMUX.O rise 5% to $1.08 premarket

** Co says it appointed Jon Congleton to its board; he helped launch Teva’s multiple sclerosis drug Copaxone in the United States

** Congleton has also served as CEO of Mineralys Therapeutics, Impel NeuroPharma and Nivalis Therapeutics,

** Adds it is developing vidofludimus calcium, an oral experimental drug for relapsing multiple sclerosis, a form of the disease with recurring flare‑ups

** Co says late‑stage study readouts for the drug are expected by the end of 2026

** Multiple sclerosis is a disease in which the immune system attacks nerves, leading to problems with movement and vision

** Shares fell ~47% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment